Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Manhattan Scientifics Acquires Exclusive Rights to Nanomedicine Technology for Early Cancer Detection and Treatment

Abstract:
Ground-Breaking Technology Developed by Dr. Edward R. Flynn Requires No Radiation and is 100x More Sensitive Than Existing Diagnostics; Techniques Enable Early Cancer Detection and Precise, Image Guided Cancer Therapies

Manhattan Scientifics Acquires Exclusive Rights to Nanomedicine Technology for Early Cancer Detection and Treatment

Albuquerque, NM | Posted on February 25th, 2010

Manhattan Scientifics Inc. (OTCBB: MHTX), a nanomedicine technology transfer and commercialization pioneer, today announced completion of its agreement to acquire all commercial rights to the body of work of nuclear physicist Edward R. Flynn, PhD and his company, Senior Scientific LLC. The breakthrough technology focuses on the emerging field of nanomedicine, with an emphasis on the early detection and localization of cancer and other diseases, and providing image-guided therapy for treatment. Financial details of the agreement were not disclosed.

Early detection of cancer can be critical to effective treatment. For example, current mammography cannot detect a breast cancer tumor until it has grown to over ten million cells. Dr. Flynn's technology has proven the ability to detect breast cancer tumors while they are only 1% that large, resulting in a hundred-fold increase in sensitivity and early detection. The new technology has demonstrated similar performance in detecting ovarian cancer, a cancer with no effective screening techniques. It has also demonstrated effectiveness in monitoring chemotherapy for leukemia, allowing more effective treatment with fewer side effects. Dr. Flynn's work has been supported for eight years by 9 grants from the National Institutes of Health and one from the U.S. Department of Defense. The technology is protected by issued and pending patents.

Dr. Flynn explains, "Our approach uses sophisticated magnetic field sensors to measure extremely small magnetic fields emitted by magnetic nanoparticles that have been injected into the body and targeted specifically toward cancer cells. This method yields high contrast images of tumors compared to normal cells. With this biomagnetic imaging technique, it is possible to identify and image small clusters of cancer cells, providing the ability to find cancer at a substantially earlier stage than is presently possible. This technology has a distinct advantage over other imaging methods in that it detects only particles bound to targeted cells and is not sensitive to unbound particles where other methods may be overwhelmed by the unbound particles. It is done without the use of ionizing radiation. This biomagnetic sensor method is applicable to breast, ovarian, leukemia, prostate, and potentially to many other cancers."

"Over the last four years in serving as science advisor to Governor Richardson, I have seen numerous technologies being developed in New Mexico. Only two have stood out as truly revolutionary. Of those two, the effort by Ed Flynn and his group is the one that is poised to have the greatest impact on the human condition. This is a great example of the kind of progress that is possible when a highly talented scientist takes an interdisciplinary approach to solving a critical health challenge," said Thomas J. Bowles, who previously served as the Chief Science Officer of Los Alamos National Laboratory, where he had oversight of $100 million annually in discretionary research funds and interfaced with other R&D institutions.

Manny Tsoupanarias, CEO of Manhattan Scientifics, commented, "Following the path of our established business model, we intend to work in close cooperation with pharmaceutical companies and world-class medical device manufacturers to bring this technology to the global market. We are currently defining initial business opportunities for the technology, and we are exploring strategic relationships with companies possessing the expertise, marketing skills, and capital to bring product to market under royalty bearing agreements. The Company has demonstrated its ability to ‘partner' with a Fortune 1000 industrial company, Carpenter Technology Corporation (NYSE: CRS), in another of its nano technology developments, producing revenue and earnings for Manhattan Scientifics."

"I've helped build companies in the past with hundreds of millions of dollars of value created for shareholders in high technology areas, but have never before been so excited about a medical advancement with such profound implications for humanity," said Marvin Maslow, former Chairman of Manhattan Scientifics and currently its leading commercialization consultant.

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

####

About Manhattan Scientifics
Manhattan Scientifics Inc. (OTCBB: MHTX) is a pioneer in the field of nanomedicine technology transfer and commercialization. Focused on disruptive technologies for diagnostic, therapeutic and prosthetic purposes, Manhattan Scientifics is presently developing commercial medical prosthetics applications for its ultra fine grain metals, and plans to commercialize the cancer research work developed by Edward R. Flynn, PhD and Senior Scientific, LLC. The company is located in New Mexico, New York and Montreal. Additional information is available at www.mhtx.com.

For more information, please click here

Contacts:
Manhattan Scientifics, Inc.
Marvin Maslow
917-923-3300

Copyright © Manhattan Scientifics

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Nanoparticle technology triples the production of biogas October 23rd, 2014

SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014

Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

Patents/IP/Tech Transfer/Licensing

Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014

harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014

Nanobiotechnology

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Nanoparticle technology triples the production of biogas October 23rd, 2014

Mechanism behind nature's sparkles revealed October 22nd, 2014

‘Designer’ nanodevice could improve treatment options for cancer sufferers October 22nd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE